Joan Ballesteros Selected Research

ibrutinib

5/2018

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joan Ballesteros Research Topics

Disease

4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 08/2014
2	Body Weight (Weight, Body) 11/2016 - 01/2014
2	Obesity 11/2016 - 01/2014
1	Neoplasms (Cancer) 01/2019
1	Primary Myelofibrosis (Myelosclerosis) 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2018

Drug/Important Bio-Agent (IBA)

2	Drug CombinationsIBA 01/2021 - 08/2014
1	AnthracyclinesIBA 01/2019
1	nilotinib FDA Link 01/2019
1	ruxolitinibIBA 01/2019
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	idelalisibIBA 05/2018
1	ibrutinibIBA 05/2018
1	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2016
1	Liraglutide FDA Link 11/2016
1	Triglycerides (Triacylglycerol)IBA 11/2016
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2014
1	disodium (R,R)- 5- (2- ((2- (3- chlorophenyl)- 2- hydroxyethyl)- amino)propyl)- 1,3- benzodioxole- 2,3- dicarboxylateIBA 01/2014

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2021
1	Palliative Care (Palliative Therapy) 01/2019
1	Therapeutics 01/2019
1	Precision Medicine 08/2014